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Abstract
Osteoporosis is a growing problem in an ageing society. It affects women of post-menopausal age, as well as elderly subjects of both sexes,
often with dysfunction of the cardiovascular system or with an increased risk of circulation disorders.
It has been found that the mortality rate of subjects with osteoporosis is comparable to that of patients suffering from such diseases as
obturative pulmonary disease or myocardial ischaemia.
Bisphosphonates are the most thoroughly studied group of drugs prescribed for the treatment of osteoporosis. Their administration is,
however, associated with a risk of adverse symptoms, which can occur as gastro-intestinal tract disturbances, muscular-osseous pains,
mandible necrosis, atypical fractures and other symptoms. Recently, there has been discussion about an increased risk of atrial fibrillation
in bisphosphonate-using female patients. This paper focuses on this particular problem, while summing up the actual status of knowledge
regarding possible associations of bisphosphonates with cardiac rhythm disturbances. (Pol J Endocrinol 2011; 62 (1): 93–96)
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Streszczenie
Osteoporoza jest narastającym problemem starzejącego się społeczeństwa. Dotyczy kobiet w wieku pomenopauzalnym i ludzi starszych
obu płci, często z dysfunkcją układu sercowo-naczyniowego lub zwiększonym ryzykiem chorób układu krążenia. Stwierdzono, że śmier-
telność osób chorujących na osteoporozę jest porównywalna z pacjentami chorującymi na takie choroby, jak obturacyjna choroba płuc,
choroba niedokrwienna serca i inne.
Bisfosfoniany są najlepiej przebadaną grupą leków stosowanych w terapii osteoporozy. Z ich przyjmowaniem wiąże się ryzyko wystąpie-
nia objawów niepożądanych, w tym zaburzeń ze strony przewodu pokarmowego, bólów mięśniowo-kostnych, martwicy żuchwy, atypo-
wych złamań i innych. W ostatnim czasie pojawiły się informacje o wzroście ryzyka migotania przedsionków u pacjentek stosujących
bisfosfoniany. Praca ma na celu zwrócenie uwagi na problem i podsumowanie aktualnego stanu wiedzy na temat powiązań bisfosfonia-
nów z zaburzeniami rytmu serca. (Endokrynol Pol 2011; 62 (1): 93–96)
Słowa kluczowe: bisfosfoniany, osteoporoza, migotanie przedsionków
Introduction
Atrial fibrillation (AF) is the most frequent disturbance
of cardiac rhythm observed in clinical practice, account-
ing for approximately one in three hospitalisations for
abnormal cardiac rhythm, which, in turn, is associated
with risks of increased morbidity and mortality rates
with their related economic impacts [1]. During the last
20 years, the number of hospitalisations for atrial fibril-
lation has risen by 66%.
The number of atrial fibrillation incidents doubles
with each life decade after the age of 55, attaining its
peak between the 85th and the 94th years of life [2, 3];
after the 75th year of life, it affects more frequently wom-
en than men (60 vs. 40%) and grows twice as fast in
Caucasians as opposed to the black population [4–6].
The initial information regarding AF episodes in the
course of therapy with bisphosphonates appeared dur-
ing the analysis of results of the HORIZON randomised,
double-blind study (Pivotal Fracture Trial) [7] (Fig. 1).
The patients who received zoledronate intravenously
demonstrated more episodes of severe cardiac rhythm
disturbances, such as atrial fibrillation, than did the pla-
cebo-receiving control group. The term ‘severe inci-
dents’ refers to those cases which require hospitalisa-
tion, intensive treatment, lifestyle change and which are
often terminated by the patient’s death. In the report-
ed study, the groups did not differ regarding the inci-
dence of other cardiac rhythm disturbances.
The appearance of that information prompted sub-
sequent studies, including a retrospective analysis of the
FIT study, in which alendronate, an oral form of bis-
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phosphonate, was given at a dose of 10 mg daily to
women with post-menopausal osteoporosis [8]. Despite
the lack of statistically significant differences in bispho-
sphonate-administered patients, a tendency emerged
towards a higher incidence of severe AF episodes vs.
the placebo-receiving group (RR 1.51 with 95% CI, 0.97–
–2.40) [9]. The prevalence of all the AF incidents did not
differ between the groups.
In another HORIZON study (Recurrent Fracture
Trial) [10], no changes were demonstrated in the inci-
dence of atrial fibrillation episodes, either severe or any
other, between the group of zoledronate-using patients
and the placebo group. Similarly, analysing the results
from a randomised study with a control group of risedr-
onate (another bisphosphonate) no differences were
found between the active drug and the control [11].
In another study, a reverse situation was evaluated,
i.e. the number of bisphosphonate-using subjects, both
at the time of the study and at any other time, in a group
of patients with AF episodes vs. a group of patients with
no cardiac rhythm disturbances [12, 13]. In the first of
those two studies, a group of 719 women with AF was
compared to a group without cardiac rhythm disorders
[12]. In the patients with AF, 6.55% of women had been
treated with alendronate at any time, vs. 4.15% of wom-
en without AF (p < 0.05). It was concluded that the risk
of AF was higher in the alendronate-using group vs.
the alendronate-naïve group (RR 1.86, 95% CI, 1.09–
–3.15). Contrary to the findings in the American study
group, the Danes did not find any increased risk of AF
[13]. In a study group of 13,586 women with AF or flut-
ter in their history, 3.2% had used bisphosphonates vs.
the group of 68,054 healthy women, in whom bisphos-
phonates (etidronate or alendronate) had been used by
2.9% of the patients (RR 0.95, 95% CI, 0.84–1.07).
Summing up those two clinical studies, a higher in-
cidence of severe episodes of AF was found. This may
suggest that in patients predisposed to cardiac rhythm
disturbances for any reason, an administration of bis-
phosphonates may initiate cardiac rhythm disorders.
Until more data is collected on the relationship between
bisphosphonates and atrial fibrillation, the therapy
should be implemented with great care regarding all
patients with cardiovascular diseases, giving priority to
the therapeutic advantages over the possible danger of
complications. On the other hand, the lack of data from
prospective studies should not limit the possibility of
bisphosphonate applications, nor be the reason for ther-
apy withdrawal [14].
Analysing various parameters emphasised the role
of gender (more often men), ageing, the quantity of used
drugs, and the use of hypertensives, as  risk factors for
AF [15]. Moreover, it has been observed that, in the
course of alendronate therapy of patients with diabe-
tes mellitus, the risk of atrial fibrillation was higher than
in subjects without metabolic disorders [12]. The prev-
alence of atrial fibrillation and flutter was also compared,
as well as the cases of acute coronary incidents in
Figure 1. The risk of atrial fibrillation (all cases, serious cases) following Mak et al. [18] in own modification. BP — bisphosphonates;
AF — atrial fibrillation
Rycina 1. Ryzyko występowania migotania przedsionków (wszystkich przypadków, ciężkich przypadków) na podstawie Mak i wsp.
[18] w modyfikacji własnej. BP — bisfosfoniany; AF — migotanie przedsionków
95
Endokrynologia Polska/Polish Journal of Endocrinology 2011; 62 (1)
PR
A
C
E 
PO
G
LĄ
D
O
W
E
27 out of 257 patients treated for osteoporosis with al-
endronate at a daily dose of 10 mg, a weekly dose of
70 mg, and with raloxifene [16].
Compared to raloxifene, alendronate did not in-
crease the risk of AF or acute coronary syndromes. How-
ever, analysing a group of patients with cardiological
problems in their history and who had received drugs
for circulation diseases for at least one year, a statisti-
cally significant increase in the number of acute coro-
nary syndromes was found vs. the medical agents of
the SERM group. In turn, alendronate, when received
less frequently, exerted a smaller risk vs. its form ad-
Table I. Biochemical structure and division of bisphospho-nates according to antiresorptive potential
Tabela I. Struktura biochemiczna i podział bisfosfonianów według potencjału antyresorpcyjnego
Generation Chemical structure Biochemical Drug Antiresorptive
— lateral chain structure potential
I Alkyl Etidronate 1
Halide Clodronate     10
II Cyclic Tiludronate 10
Cyclic Pamidronate 100
Amine Alendronate 100–1000
III Pyridinyl Cyclic  Risedronate 1000–10 000
Cyclic Ibandronate 1000–10 000
Cyclic Zoledronate ≠10 000
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ministered once daily. The authors drew the conclu-
sion that chronic administration of alendronate should
not be suggested to women with cardiological problems
in their history.
Cardiac complications appeared more frequently
after strong bisphosphonates (Table I), i.e. zoledronate
and alendronate [17, 18]. The mechanism by which bis-
phosphonates induce AF has yet to be entirely under-
stood. Perhaps, the drugs enhance the susceptibility
towards cardiac rhythm disorders, decreasing the con-
centrations of calcium and phosphates [19, 21], similarly
as in hypocalcaemia in the course of secondary hyper-
parathyroidism in dialysed subjects [22]. The atrium
demonstrates high sensitivity to calcium concentration
reductions [23]. It seems, however, that in the case of
bisphosphonates, there is too little data to back up such
a thesis [17]. This is confirmed by the observations of
Black et al. [7] who found no differences after zoledr-
onate in calcium or phosphate concentrations in patients
with or without AF.
The arrhythmogenic activity of proinflammatory
cytokines, secreted during parenteral administration of
bisphosphonates, may be regarded as another expla-
nation of the issue [24, 25]. However, analysing the time
of the complication’s appearance in various studies, it
was found that atrial fibrillation could not be regarded
as an acute complication of the applied therapy [7, 9].
Most often, the incident occurred after at least one year
of therapy, enhancing after four years of zoledronate
administration and after a period longer than 30 days
from infusion (47–50 days). Another aspect should also
be taken into consideration. Certain adverse effects, e.g.
influenza-like symptoms, occur after nitrogen contain-
ing bisphosphonates, including alendronate and zoledr-
onate [26]. There have been few studies concerning AF
in the course of aminobisphosphonates, and their re-
sults are unclear [17, 18]. Even if no greater number of
incidents were observed after alendronate as opposed
to etidronate [13], the difference against alendronate
was distinct in a group of patients with increased mor-
bidity and using multiple drugs [15].
Summing up, doctors and patients should pay at-
tention to the advantages and risks associated with the
use of drugs. In women at high risk of AF and small
risk of fractures, a particularly close consideration of the
issue would be advisable. But for most patients at high
risk of fractures, the advantages of bisphosphonate ther-
apy may be more important for their general health sta-
tus than the risks of atrial fibrillation [7, 9, 10].
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